A South African pharmaco-economic analysis of the acute infarction ramipril efficacy (AIRE) Study

Cardiovascular Journal of South Africa

Volumn 11, Issue 2, 2000, Pages 89-94

  Nixon Anderson, A ^a   Moodley, Indres ^b   Kropman, Keith ^a  

^a Anderson Kropman cc   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMIPRIL;

ACUTE HEART INFARCTION; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH ECONOMICS; HEART FAILURE; HUMAN; MORTALITY; QUALITY ADJUSTED LIFE YEAR; SOUTH AFRICA;

EID: 0033913508     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Erhardt L, Ball S, Andersson F, Bergentoft P, Martinez C. Cost effectiveness in the treatment of heart failure with ramipril. Pharmacoeconomics 1997; 12(2 Pt 2): 256-266.
2. Schädlich PK, Huppertz E, Brecht JG. Cost effectiveness analysis of ramipril in heart failure after myocardial infarction. Pharmacoeconomics 1998; 14: 653-669.
3. Health Systems Trust, Henry J Kaiser Family Foundation. South African Health Review 1996. Durban: Fishwick Printers, 1996.
4. Health Systems Trust. South African Health Review 1997. Durban: Kwik Kopy Printing, 1997.
5. Garg R, Yusuf S. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-1456.
6. Ball SG, for the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
7. Hall AS, Murray GD, Ball SG, for the AIREX Study Investigators. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997, 349: 1493-1497.
8. Martinez C, Ball SG. Cost-effectiveness of ramipril therapy for patients with clinical evidence of heart failure after acute myocardial infarction. Br J Clin Pract 1995; 49: suppl 78, S26-S32.
9. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost-effectiveness league tables. BMJ 1993; 306: 570-572.
10. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford: Oxford University Press, 1997.
11. Andersson F, Cline C, Rydén-Bergsten T, Erhardt L. Angiotensin converting enzyme (ACE) inhibitors and heart failure. Pharmacoeconomics 1999; 15: 535-550.
12. Brown N, Melville M, Gray D, et al. Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population. Heart 1999; 81: 352-358.
13. Yusuf S, Sleight P, Prague J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-153.